In silico investigation of Panax ginseng lead compounds against COVID-19 associated platelet activation and thromboembolism

• Published in: Journal of ginseng research Vol. 47; no. 2; pp. 283 - 290
• Main Authors: Yixian Quah, Yuan Yee Lee, Seung-Jin Lee, Sung Dae Kim, Man Hee Rhee, Seung-Chun Park
• Format: Journal Article
• Language: Korean
• Published: 2023
• Subjects: COVID-19; molecular docking; hypercoagulability; Panax ginseng; platelet aggregation
• ISSN: 1226-8453; 2093-4947

Hypercoagulability is frequently observed in patients with severe coronavirus disease-2019 (COVID-19). Platelets are a favorable target for effectively treating hypercoagulability in COVID-19 patients as platelet hyperactivity has also been observed. It is difficult to develop a treatment for COVID-19 that will be effective against all variants and the use of antivirals may not be fully effective against COVID-19 as activated platelets have been detected in patients with COVID-19. Therefore, patients with less severe side effects often turn toward natural remedies. Numerous phytochemicals are being investigated for their potential to treat a variety of illnesses, including cancer and bacterial and viral infections. Natural products have been used to alleviate COVID-19 symptoms. Panax ginseng has potential for managing cardiovascular diseases and could be a treatment for COVID-19 by targeting the coagulation cascade and platelet activation. Using molecular docking, we analyzed the interactions of bioactive chemicals in P. ginseng with important proteins and receptors involved in platelet activation. Furthermore, the SwissADME online tool was used to calculate the pharmacokinetics and drug-likeness properties of the lead compounds of P. ginseng. Dianthramine, deoxyharrtingtonine, and suchilactone were determined to have favorable pharmacokinetic profiles.